Tricida, Inc. is listed today as Tricida: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2017 | $58 M | No. 4 | $50 to $250 million | equity | SEC | |
| Jul 2016 | $24 M | No. 3 | $10 to $50 million | equity | SEC | |
| Feb 2015 | $17 M | No. 2 | $10 to $50 million | equity | SEC | |
| Dec 2013 | $5 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Tricida, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2017).
SEC Form D · Nov 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2017
That is all the official record says: Tricida, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Tricida, Inc. are on record.
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Hadley Harbor Master Investors (Cayman) II L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Longitude Capital Partners II, LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Longitude Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| OrbiMed Capital GP V LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Fund II-A L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Fund II-B L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Fund II-C L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Fund II-D L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Ventures III LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Ventures II LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Ventures IV LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Capital Ventures LLC | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Sibling Co-Investment LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 13 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Claire Lockey | Executive officer | Nov 2017 |
| Edward Hejlek | Executive officer | Nov 2017 |
| Geoffrey Parker | Executive officer | Nov 2017 |
| Gerrit Klaerner | Executive officer | Nov 2017 |
| Jerry Buysse | Executive officer | Nov 2017 |
| Wilhelm Stahl | Executive officer | Nov 2017 |
| Melissa Miksch | Executive officer | Feb 2015 |
| David Bonita | Director | Nov 2017 |
| David Hirsch | Director | Nov 2017 |
| Gerrit Klaerner | Director | Nov 2017 |
| Klaus Veitinger | Director | Nov 2017 |
| Robert Alpern | Director | Nov 2017 |
| Sandra Coufal | Director | Nov 2017 |
About
Pharmaceutical company.